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Cytokinesis is the ﬁnal stage of cell division during which the two daughter cells separate com-
pletely. Although less well understood than some of the earlier phases of the cell cycle, recent dis-
coveries have shed light on the mechanisms that orchestrate this process, including cleavage furrow
formation, midbody maturation and abscission. One of the reasons why research on cytokinesis has
been attracting increasing attention is the concept that failure of this process in mammals is asso-
ciated with carcinogenesis. In this minireview, we will discuss the possible links between cytokine-
sis and cancer, and highlight key mechanisms that connect these processes.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Cytokinesis is the physical separation of two daughter cells dur-
ing cell division and is the ﬁnal stage of the cell cycle [1]. After ana-
phase and chromosomal segregation, cells form a contractile ring
which is a network of actin and myosin ﬁlaments, to drive the con-
striction of the plasma membrane, so that two daughter cells con-
nected by a cytoplasmic bridge are generated. This intracellular
bridge contains the midbody, which is resolved during the ﬁnal
stage of abscission [2]. Failure to complete cytokinesis has been
proposed to promote tumourigenesis [3–5] by leading to tetra-
ploidy [3,4,6] and ensuing chromosomal instability. Theodor Bove-
ri was the ﬁrst to introduce the idea that there might be a
connection between abnormal mitosis and malignant tumours.
He characterized the centrosome in 1888 and suggested that a cell
with multiple centrosomes would lead to genomic instability and
cancer. He proposed that this could happen either because of
abnormal division of the centrosomes or by suppression of cell
division, which would then lead to tetraploidy [7]. Since these
early observations, many studies have provided support for Bove-
ri’s hypothesis, and here we review some of the key recent
ﬁndings.
Normal mammalian somatic cells do not have any speciﬁc
mechanism that arrests binucleate cells in G1 phase so as to pre-chemical Societies. Published by E
mistry, Institute for Cancer
rsity Hospital, Montebello, N-
rk).vent their propagation in case of cleavage failure. As a result, cleav-
age failure is a factor that can lead to tetraploidy and aneuploidy,
and potentially to tumourigenesis [8]. However, it still remains
controversial whether tetraploidy and genomic instability are the
cause or result of cancer. Recent observations indicate that APC
(adenomatous polyposis coli) mutations found in human colorectal
cancer may inhibit cytokinesis by preventing mitotic spindle
anchoring at the anaphase cortex and thus blocking initiation of
cytokinesis. This supports the idea that tetraploidy may represent
a ﬁrst step in genomic instability and eventually cancer [6]. More-
over, it was recently found that abscission mediated via inactiva-
tion of the regulatory kinase Aurora B promotes completion of
chromosome segregation and thus protects against tetraploidiza-
tion and cancer [5]. In this review, we will discuss the mechanisms
of cytokinesis and provide possible links between this process and
carcinogenesis.2. Mechanisms of cytokinesis in animal cells
2.1. Cytokinesis, the ﬁnal stage of mitosis
The cell cycle consists of the distinct phases G1, S (DNA synthe-
sis) and G2, collectively known as interphase, and M (mitosis). It
is well established that a family of kinases, the cyclin-dependent
kinases (CDKs) are responsible for driving cells from G2 phase into
M phase that leads ﬁnally in chromosomal segregation. In order
to achieve this, they recruit downstream transducers, which will
be discussed below, that act directly on various components oflsevier B.V. All rights reserved.
Fig. 1. Immunoﬂuorescence images showing HeLa cells in late phases of the cell cycle. Aurora B is shown in red and DNA in blue. By anaphase, the spindle is elongated. By late
anaphase the cleavage furrow starts to ingress and by early telophase the furrow is fully ingressed and the spindle is compacted into the midbody. By late telophase-
cytokinesis, the midbody is narrowed and the cell is prepared for abscission.
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[9]. Mitosis can be subdivided into prophase, prometaphase, meta-
phase, anaphase, telophase and cytokinesis (Fig. 1). Cytokinesis
was described more than 100 years ago, and the role of actin and
myosin in cleavage as well as the role of the mitotic spindle were
described more than 30 years ago [10]. Ever since, there has been
an increasing rate of research in the cytokinesis ﬁeld, and many re-
cent ﬁndings have provided more detailed information concerning
the molecular mechanisms of cytokinesis, including an extensive
list of proteins that are involved (Table 1).
2.2. Early cytokinesis
In animal cells, cytokinesis begins with the assembly of a cen-
tral spindle during anaphase [11]. Multiple proteins control the
dynamics of the central spindle [12]. The most important are the
microtubule associated protein (MAP) PRC1, the centralspindlin
complex MKLP1 (mitotic kinesin-like protein 1) and the chromo-
some passenger complex (CPC). PRC1, a mitotic spindle associated
CDK substrate, is a microtubule binding and bundling protein re-
quired to maintain the spindle midzone [13]. PRC1 is phosphory-
lated by CDK1 (Cdc2/Cyclin B) in early mitosis and turns into an
inactive and monomeric state. During the metaphase-anaphase
transition PRC1 is dephosphorylated and as a result interacts with
KIF4, a kinesin motor that translocates PRC1 along mitotic spindles
towards the plus end of antiparallel interdigitating microtubules.Through its dephosphorylation, PRC1 is oligomerized, and this pro-
motes its microtubule bundling activity. More speciﬁcally, the plus
end–associated, dephosphorylated PRC1 proteins bundle the anti-
parallel interdigitating microtubules to form the midzone which
serves as a platform for the localization of the other critical pro-
teins of the spindle, such as centraspindlin and chromosome pas-
senger complex [14]. Centraspindlin is a heterotetramer that
consists of MKLP-1 and CYK-4, which contains a GTPase-activating
protein (GAP) domain for Rho GTPases. As a whole heterotetramer,
containing two molecules of MKLP-1 and two molecules of CYK-4
RhoGAP, it promotes microtubule bundling in vitro [15] and RhoA
regulation and recruits regulators of abscission [2].
The chromosome passenger complex is important for chromo-
some segregation and cytokinesis and consists of survinin, borealin
and INCENP (inner centromere protein). These components regu-
late the activity and localization of the protein kinase Aurora B,
the enzymatic component of CPC. The N-terminal domains of bore-
alin and INCENP together with survinin form the core of CPC,
which is required for targeting to the central spindle and the mid-
body. For the centromere targeting, also the C-terminal domain of
borealin is required. Aurora B interacts with the core by binding to
the IN-box (the conserved C-terminal region) of INCENP, and IN-
CENP regulates the localization of Aurora B by interacting with
borealin and survinin via its N-terminal domain [16].
The translocation of CPC from centromeres to the spindle mid-
zone during anaphase is important for completing cytokinesis.
Table 1
Examples of proteins that mediate or regulate cytokinesis.
Microtubule-associated proteins
PRC1 [13,14]
Centralspindlin complex
CYK-4 [2,15]
MKLP1 [2,15]
Chromosome passenger complex
INCENP [16,17]
Survinin [16,17]
Borealin [16,17]
Aurora B [16,17]
ESRCTs and associated proteins
CEP55 [30–32]
TSG101 [31,32]
ALIX [31,32]
CHMP1B [33]
Spastin [33]
CHMP4B [31,32,34]
FYVE-CENT [34]
TTC19 [34]
Kinesins
KIF4A [14]
MKLP2 [17]
MPP1 [22]
KIF14 [23]
KIF13A [34]
Additional proteins
NuSAP [18]
Orbit [19]
ASP [20]
TBCD [21]
ECT2 [24]
FIP3 [25]
PLK1 [26,27]
Septins [28]
Anillin [29]
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fer of CPC in the central spindle, thus resulting in cytokinesis de-
fects [17].
Apart from the proteins described above, which are the compo-
nents of the central machinery of the spindle, there are many other
proteins that concentrate on the central spindle during anaphase
and telophase, including NuSAP, Orbit and ASP. NuSAP (nucleolar
spindle-associated protein) is a microtubule associated protein
(MAP) whose overexpression or depletion results in defects in cell
proliferation, suggesting that it is involved in the mitotic spindle
organization [18]. Orbit is also a MAP, ﬁrst characterized in
Drosophila melanogaster. It is required for the functional kinetochore
attachment of microtubules and in order to maintain spindle
polarity [19]. Another MAP, ASP (abnormal spindle), was also ﬁrst
identiﬁed in D. melanogaster. Mutations in ASP result in abnormal
spindle poles [20]. Another protein found at the central spindle is
tubulin cofactor D (TBCD). This protein localizes to the centrosome
and to the midbody and contains a microtubule-binding region and
two centriolar targeting regions. TBCD participates in spindle orga-
nization, cell abscission and in centriologenesis. Depletion of TBCD
results in mitotic defects and incomplete microtubule retraction at
the midbody during cytokinesis [21].
The importance of microtubule-driven processes during cell
division is illustrated by the abundance of kinesin motors in the
central spindle. KIF4A interacts with PRC1 and translocates it to-
wards the plus end of microtubules [14]. MKLP2 is also a mitotic
kinesin, essential for recruitment of CPC to the spindle zone. IN-
CENP is required for the localization of MKLP2 and vice versa,
and these proteins are both negatively regulated by CDK1 [17].
MPP1 (M phase phosphoprotein 1) is a plus-end-directed kinesin
related protein with microtubule binding and bundling properties.Its knockdown results in failure of cytokinesis, indicating that it
has an important role in cytokinesis [22]. Another kinesin, KIF14
has also an important role in cell division. The level of KIF14 has
been correlated with mitotic progression in the cell cycle and this
protein, together with its interactors PRC1 and citron kinase plays
an important role in cytokinesis during midbody formation and in
the completion of cytokinesis [23].
Many proteins important for cytokinesis act as subunits of lar-
ger complexes. One example is ECT2, a guanine nucleotide ex-
change factor for Rho GTPases that localizes to the central
spindle by binding to centralspindlin. ECT2 interacts with CYK-4
in cell cycle regulated manner, meaning that the interaction is
weak during metaphase when ECT2 is phosphorylated and in-
creases during anaphase when ECT2 is dephosphorylated. CYK-4
and ECT2 are essential for RhoA localization, and CYK-4 can act
as an activator of ECT2 [24]. Close to this complex of proteins
comes FIP3, which is important for late cytokinesis and is a class
II Rab11 family interactive protein. FIP3 binds to CYK-4 at late telo-
phase, and for its recruitment in the midbody centralspindlin com-
plex is required. The FIP3-binding region on CYK-4 overlaps with
the ECT2-binding domain. FIP3 and ECT2 form exclusive complexes
with CYK-4 and removal of ECT2 from the centraspindlin complex
at late telophase is required for the recruitment of FIP3-containing
endosomes to the cleavage furrow [25]. Another important protein
of this complex is PLK1 (polo-like kinase 1) which binds to micro-
tubules and interacts with MKLP2. Phosphorylation of MKLP2 by
PLK1 is required for the localization of PLK1 to the central spindle
during anaphase and telophase and the complex of these two pro-
teins is necessary for the completion of cytokinesis [26]. It is also
shown that PLK1 is important for the binding of ECT2 to CYK-4
and its recruitment to the midzone, thus promoting the initiation
and completion of cytokinesis. It functions after CDK1 inactivation
and independently from Aurora B [27].
Septins were ﬁrst identiﬁed in a screen for genes essential for
yeast cell division. These GTP-binding proteins form a ring of 10-
nm ﬁlaments adjacent to the plasma membrane at the mother-
bud neck junction at the time of bud emergence and disassemble
prior to cytokinesis. In yeast, septins are important for the orienta-
tion of the spindle polar body, and they act as cell-cycle check-
points. Mutations in yeast septin genes result in the inability to
complete cytokinesis. The role of septins in mammalian cytokine-
sis is less clear, but depletion of SEPT2 or SEPT9 results in impaired
cytokinesis and in an accumulation of binucleated cells as well as
cells arrested at the midbody stage [28]. This suggests that septins
play a conserved role in cytokinesis. The septin-interacting protein
anillin localizes to the cleavage furrow and interacts with several
other furrow components, such as F-actin and myosin II. Depletion
of anillin causes furrow instability, suggesting that anillin serves as
an organizer of the cytokinesis machinery [29].
2.3. The abscission step of cytokinesis
The mechanisms of physical cell separation during cytokinesis,
known as abscission, are still incompletely understood, but at least
three main processes are required. Firstly, membrane vesicles de-
rived from the biosynthetic and endocytic recycling pathways are
delivered to the plasma membrane of the constricting midbody
in order to facilitate further narrowing. Secondly, interdigitating
microtubules in the midbody need to be severed. Thirdly, the ﬁnal
abscission of a (presumably) thin membrane stalk that connects
the two daughter cells is required. It is striking that several centro-
somal proteins translocate to the midbody during cytokinesis, per-
haps reﬂecting the need for microtubule organization in the
midbody. One such protein is CEP55 (centrosomal protein
55 kDa) which localizes to the mitotic spindle during prometa-
phase and metaphase and to the spindle midzone and midbody
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of abscission. CEP55 binds directly MKLP1 and is controlled by cen-
tralspindlin, since knockdown of centralspindlin abolishes CEP55
from the midbody [30]. Interestingly, CEP55 also interacts with
Tsg101, an endosomal sorting complex required for transport (ESC-
RT)-I subunit, and Alix, an ESCRT-associated protein and recruits
these to the midbody. These proteins have an important role in
the ﬁnal step of abscission, presumably by recruiting subunits of
ESCRT-III, which are thought to promote membrane severing
through formation of constricting helical oligomers [31]. Depletion
of CEP55, Tsg101 and Alix results in an increased number of mul-
tinucleated cells and cells arrested at the midbody stage. The
mechanisms by which Tsg101 and Alix recruit and activate ESC-
RT-III are not entirely clariﬁed. Alix might engage ESCRT-III to
mediate ﬁnal abscission, or ESCRT-I could recruit ESCRT-III through
a direct interaction between ESCRT-I and –III subunits, as shown in
vacuolar protein sorting in yeast [32].
The mechanisms of microtubule severing during midbody
abscission have been elusive, but the ATPase spastin has recently
emerged as a mediator of this process. Spastin is found in the cen-
tral spindle and in the midbody during cytokinesis and displays
microtubule severing activity. It interacts via its microtubule inter-
acting and transport (MIT) domain with the ESCRT-III component
CHMP1B, which recruits spastin on the midbody. Overexpression
of a spastin mutant construct with an inactivated CHMP1B binding
site results in cytokinesis defect, whereas the wild type construct
has no such effect. This suggests that microtubule severing and
membrane abscission could be coordinated via the spastin-ESC-
RT-III interaction and reveals a plausible function of spastin in
abscission [33].
ESCRT proteins are best described for their functions in the bio-
genesis of multivesicular endosomes, and the sorting of ubiquiti-
nated membrane proteins into these. It is conceivable that the
midbody contains speciﬁc ESCRT-III regulators that tune these pro-
teins to mediate cell-cell abscission instead of endosome-vesicle
abscission. A candidate for such a regulator is the centrosomal pro-
tein TTC19, which translocates to the midbody during cytokinesis
and interacts directly with the ESCRT-III subunit CHMP4B
[34].The functional consequence of this interaction is not known,
but because CHMP4B is thought to be an oligomerizing subunit
of ESCRT-III, one possibility is that TTC19 might serve to control
the length or shape of the CHMP4B oligomers.
Even though little is known about the lipid composition of the
midbody, it is interesting to note that a speciﬁc membrane lipid,
phosphatidylinositol 3-phosphate (PtdIns3P), has emerged as a
regulator of cytokinesis. PtdIns3P is formed at the midbody
through the activity of class III phosphoinositide 3-kinase (PI3K-
III) and recruits a large protein, FYVE-CENT to the midbody. It is
unclear whether FYVE-CENT as such regulates cytokinesis, but it
appears to function as a scaffold for TTC19, thereby bringing this
ESCRT interactor to the midbody. The translocation of FYVE-CENT
to the midbody is driven by the kinesin-3 KIF13A, and the impor-
tance of these proteins in cytokinesis is illustrated by the ﬁnding
that depletion of PI3K-III, TTC19, FYVE-CENT or KIF13A is sufﬁcient
to cause an increased number of cells undergoing cytokinesis, and
increase in the proportion of bi- and multinucleated cells [34].
2.4. From tetraploidy to cancer
One possible consequence of abortive cytokinesis may be cleav-
age furrow regression and formation of binucleate cells. The state
in which cells contain more than two sets of chromosomes is
known as polyploidy. Polyploidy frequently occurs in nature and
is thought to be a normal situation. However, under certain cir-
cumstances polyploidy may give rise to cancer. Polyploidy can be
triggered mostly by three mechanisms: cell fusion, endoreplicationor via a series of defects that result in an abortive cell cycle
[35].Cell fusion is a process that occurs in various instances, such
as in the formation of some tissues (syncytiotrophoblasts) and in
the repair of others (liver, skeletal muscle, heart). It can also occur
during disease, usually as a result of viral infection. It is not known
whether cell fusion can happen spontaneously between cell types
that are not programmed to go through cell fusion, but it is known
that tetraploid cells can be created via cell fusion, with mixed ge-
netic material and uncertain phenotype [35,36]. Endoreplication
is another way of generating polyploid cells. In this process, cells
increase their genomic DNA content without dividing. Endoreplica-
tion occurs in mammals, insects, plants and protists and consti-
tutes an effective strategy of cell growth, often found in
differentiated cells with high metabolic activity [37]. Finally, the
abortive cell cycle is one more mechanism by which polyploid cells
can be formed. This mechanism is triggered by a variety of events,
such as DNA replication, defects in mitotic spindle function and
cytokinesis as well as dissolving sister chromatin cohesion. As a re-
sult, the cell cycle is blocked or apoptosis is triggered. In some
cases though, abortive cell cycle can result in only on delays in cell
cycle progression, which in turns leads to tetraploidy. The main
difference between abortive cell cycle and endoreplication is that
endoreplication is a normal process whereas abortive cell cycle
takes place under pathological situations [35].
Apart from these mechanisms, polyploidy can occur in cases of
cell ageing, stress and as a protection against DNA damage. In the
liver, the amount of polyploid cells increases with the age as well
as upon oxidative damage, for example after hepatectomy. An
explanation for this response could be that under limited re-
sources, such as during stress, the energetic demands for prolifer-
ation compete with the energetic requirements for differentiation
and as a result, cells that endoreplicate use the energy that would
otherwise have gone into cell division processes, for the biosynthe-
sis of extra proteins or cellular components needed in a polyploid
cell. Finally, polyploidy is thought to protect cells from genotoxic
damage by increasing their gene copy number. This idea seems
controversial though; because of the fact that it is proven in yeast
that increased DNA content in the cell is not necessarily an advan-
tage for survival in the presence of DNA-damaging conditions [35].
Centrosomes organize the microtubules in animal cells and in
general coordinate all the microtubule-related functions, such as
cell shape, adhesion and motility, polarity and intracellular trans-
port. Centrosomes are also important for chromosome segregation
and cytokinesis and they determine the position of the cleavage
plane during cytokinesis, which is important for the asymmetric
divisions and morphogenesis. The number of centrosomes that
are present in a cell determines the number of spindle poles. So,
in the case of extra centrosomes, the cell will have multipolar spin-
dles and in the case of failure in centrosome separation, the cells
will have monopolar asters. Because of the great importance of
centrosomes in cell division, they have a crucial role in cell cycle
regulation and in checkpoints [38]. Taking this in consideration,
it is expected that polyploid animal cells with many centrosomes
can have various fates. First of all, they can undergo cell cycle ar-
rest triggered by the tetraploidy checkpoint, which can mediate
apoptosis. The cells that escape from this checkpoint often con-
tinue into a multipolar mitosis, which will end in aneuploidy
and/or cell death. Rarely, a multipolar mitosis can result to a dip-
loid cell, through a process known as reduction mitosis, which
can occur either when a diploid genome is segregated to one pole
during a multipolar mitosis or by loss of chromosomes over several
cell divisions. Finally, some cancer cells with multiple centrosomes
can even go through bipolar mitosis [35].
Aneuploid cells can arise from unstable tetraploid intermedi-
ates. Apart from the alterations in the total chromosomal number,
such cells usually contain many chromosomal rearrangements,
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caretaker genes can be lost, which may lead to chromosomal insta-
bility and eventually to cancer [4,35]. In order for the cells to avoid
aneuploidy, they have evolved various protective mechanisms that
prevent proliferation and survival of genetically unstable cells. One
such mechanism is the Aurora B-controlled checkpoint that pre-
vents furrow regression in cells with perturbed chromosomal seg-
regation [5]. Also the DNA damage effector Checkpoint kinase 1
(CHK1) is important for DNA replication, intra-S phase and G2/M
phase checkpoints as well as the mitotic checkpoint. Through its
interaction with Aurora B, it serves also as a checkpoint for cytoki-
nesis and since it is a DNA damage effector works as a link between
DNA damage response and cell cycle [39]. Apart from this, a central
mechanism is the mitotic checkpoint (spindle assembly check-
point), which controls cell cycle during mitosis by preventing chro-
mosome missegregation and thus aneuploidy. The signaling
pathway of this checkpoint is well characterized. A central role in
this pathway is played by CDC20, an E3 ubiquitin ligase which is
the substrate speciﬁcity of the anaphase-promoting complex
(APC). Kinetochores on unattached chromosomes generate an
inhibitor that binds to CDC20. CDC20 in turn activates recognition
by APC of substrates such as cyclin B and securin whose ubiquiti-
nation is required for chromosome segregation during anaphase.
CDC20 binds to the mitotic checkpoint proteins MAD2, BubR1
and a complex containing both and in this way it inhibits APC-
mediated ubiquitination of cyclin B and securin and blocks ana-
phase inhibition [40].
A more general checkpoint is the tetraploidy checkpoint that
operates in G1 phase and recognizes tetraploid cells, formed either
by failure of mitotic spindle or by failure of cytokinesis. This in-
duces their arrest in a p53 dependent manner and thereby pre-
vents the propagation of errors of late mitosis and the generation
of aneuploidy. These ﬁndings came out after applying dihydrocy-
tochalasin B (DCB) in primary rat ﬁbroblasts [41]. Similar experi-
ments were repeated by other studies with lower doses of DCB,
and it has been concluded that tetraploid cells do not necessarily
arrest in G1 [8]. This was also conﬁrmed by a study showing that
tetraploidy, aberrant centrosome number, increased cell size and
failure of cytokinesis do not lead to G1 arrest [42]. It therefore
seems that there is no speciﬁc p53-dependent mechanism that ar-
rests binucleate cells in G1 phase so as to prevent them from
becoming tetraploid in case of cytokinesis failure. The combination
of these studies can be explained with the idea that cell stress and
drug treatment activates p53 protein [43]. Finally, DNA damage
triggers cell death and cell cycle arrest and it is another way that
the cell uses to maintain genome integrity when the other check-
point controls have failed [44].
3. Cell cycle and cytokinesis defects in human cancer
We have now discussed some of the proteins that are compo-
nents of the cytokinetic machinery, the factors that regulate the
cell division and the process through which tetra- and aneuploidy
may cause cancer. In this section we will provide various examples
that link cell cycle and cytokinesis defects with cancer.Table 2
Examples of cancers associated with centrosomal abnormalities.
Abnormalities in centrosomes in various cancers
Breast and prostate cancer [45–47]
Bladder cancer and Malignant biliary tract disease [48,49]
Pancreatic cancer [50]
Head and neck sguamous cell carcinoma
Oral squamous carcinomas [51–53]
Neuroectodermals tumours [54]3.1. Centrosome abnormalities and cancer
Cancer cells often have multiple centrosomes and present cen-
trosomal abnormalities in general. This is obvious in various types
of cancers (Table 2).
3.1.1. Breast and prostate cancer
Human breast tumours frequently contain alterations such as
supernumerary centrioles, excess pericentriolar material, in-
creased number of centrosomes and microtubule nucleating capac-
ity and inappropriate phosphorylation of centrosomal proteins
[45]. From a study in which breast tumours were analyzed for
aneuploidy and chromosomal instability, it was revealed that cen-
trosome size and number correlate with aneuploidy and chromo-
somal instability, whereas microtubule nucleation capacity does
not, even though it correlated signiﬁcantly with loss of tissue dif-
ferentiation. Also, centrosome ampliﬁcation and chromosomal
instability occurred independently of p53 mutation. However,
p53 mutation was responsible for signiﬁcant increase in centro-
some microtubule nucleation capacity. These data suggest that
independent aspects of centrosome ampliﬁcation correlate with
chromosomal instability and loss of tissue differentiation and
could be involved in tumour development and progression
[46].Centrosome defects are also observed in prostate cancer sam-
ples. In this report, 109 tissue sections from radical prostatecto-
mies with invasive carcinoma and 31 cases from metastatic
prostate carcinoma were analyzed. Using pericentrin as a marker,
it was revealed that centrosomes were structurally and numeri-
cally abnormal in the majority of the samples and the abnormality
increased with the increasing genomic instability and in the most
severe prostate cancer samples. Thus, pericentrin could be possibly
used as prognostic marker for prostate cancer progression [47].
3.1.2. Bladder cancer
Bladder cancer samples frequently contain a number of centro-
somes that is signiﬁcantly increased compared to normal tissue,
presumably as a result of cytokinesis failure. Interestingly this is
correlated with an increase in chromosome numbers [48]. Centro-
some abnormalities have been detected also in malignant biliary
tract diseases. Forty malignant biliary diseases including gallblad-
der cancers (GC), intrahepatic cholangiocellular carcinoma (CCC)
and extrahepatic bile duct cancers (BDC) were examined. It was
found that 70% of the GC, 58% of the CCC and 50% of the BDC sam-
ples presented centrosome abnormalities and signiﬁcantly higher
compared to the benign controls. It was also noticed that in the ad-
vanced stage of malignancy the centrosomal abnormalities were
much higher compared to the early stage, indicating that centro-
some abnormality could be associated with the transition from
early to advanced stage of malignancy in biliary tract malignant
diseases [49].
3.1.3. Pancreatic cancer
From analyses of ductal carcinomas, adenomas, endocrine tu-
mours, chronic pancreatitis as well as normal pancreatic tissues
it has been revealed that 85% of the carcinomas and some adeno-
mas displayed abnormal centrosomal proﬁles, characterized by
an increase in size and number of centrosomes as well as irregular
distribution. On the contrary, none of the normal ductal and stro-
mal tissues showed these abnormalities, suggesting that centro-
somal abnormalities occur in the early stage of pancreatic ductal
carcinogenesis [50].
3.1.4. Squamous cell carcinomas
Centrosome abnormalities are also found in head and neck
squamous cell carcinoma (HNSCC). In a recent study, tumour sam-
ples from 18 patients with HNSCC were analyzed, and in 17 of
Table 3
Examples of cell cycle and cytokinesis regulators that are mutated or aberrantly
expressed in various cancers.
Gene/protein
mutated in cancer
Type of cancer
p53 and associated proteins
p53 Colon, lung, esophagus, breast, liver, brain
reticuloendothelial tissues, hemopoietic tissues
cancer etc. [55]
14-3-3 isoform r Prostate and breast cancer [56]
p21WAF1/CIP1 Hepatitis B virus multistep hepatocarcinogenesis
[57]
Mitotic checkpoint proteins
MAD2 Breast cancer [58]
BUB1 Colorectal cancer [59]
Rad9 Breast cancer [60]
ATM Leukemia and lymphoid malignacies [61]
CHK1 Lymphoid neoplasms [62,39]
CHK2 Li-Fraumeni syndrome, Hodgkin’s lymphoma, urinary
bladder cancer [63–65]
chfr Lung cancer [66]
BRIT1 Breast cancer cell lines, human epithelial tumours of
ovary and prostate [67]
Septins Various types of cancer, acute leukemia [68]
Anillin Various types of cancer, lung cancer [69]
Mitotic regulators
BRCA1 Breast and ovarian cancer [70]
Inositide-speciﬁc
phospholipase c b1
Myelodysplastic syndrome [71]
FEZ1/LZTS1 Primary gastric cancer, primary transitional cell
carcinoma of bladder, Bellini duct carcinoma, lung
cancer, primary esophageal and prostate cancer [72]
centrobin Lung cancer [73]
Protein kinases
Aurora A Various cancers, hepatocellular carcinoma etc. [74]
Aurora B Various cancers [5,75]
Brd4 Various cancers [75]
Aurora 2 Breast, ovarian, colon, prostate, neuroblastoma
andcervical cancer [76]
PLK1 Acute myelogenous and acute lymphoblastic leukemia
[77]
Other proteins
Rab21 Ovarian and prostate cancer [79]
KLHDC8B Classical Hodgkin lymphoma [80]
GATA6 Ovarian cancer [81]
FYVE-CENT Breast cancer [34,82]
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centage is so high, it is implied that this could be used as a marker
for HNSCC [51]. This observation is also interesting because of the
fact that the p53 suppressor gene, the most frequently mutated in
gene human cancers, is correlated with centrosome hyperampliﬁ-
cation in HNSCC. Centrosome hyperampliﬁcation is either ob-
served in p53 mutant tumours or in tumours that retain wild
type p53 but contain overexpressed Mdm2, an oncogene that
inhibits p53 transactivation function [52]. Centrosomal abnormal-
ities have also been found increased in oral squamous cell carcino-
mas in cells in which the spindle checkpoint protein CDC20 is
overexpressed [53]. This is explained because in cancer cells very
often genes that encode for proteins involved either in mitotic
checkpoints or in other important mitotic regulations are found
mutated or overexpressed.
3.1.5. Neuroectodermal tumours
Centrosome ampliﬁcation followed by numerical chromosome
aberrations has been observed in primitive neuroectodermal tu-
mours that lack the wild type p53 gene. Since p53 is important
for centrosome duplication, the conclusion of this observation is
that centrosome ampliﬁcation can occur in tumours lacking wild
type p53 and could be a mechanism for the generation of numer-
ical chromosomal aberrations [54].
3.2. Cell cycle regulators and cancer
Multiple cell cycle regulators are found mutated in various can-
cers. In this section, we will highlight some of these regulators and
their link to cancer (Table 3 and Fig. 2).
3.2.1. p53 and associated proteins
p53 is a tumour suppressor protein that is encoded by the TP53
gene. It is found mutated or deleted in a wide range of cancers,
including colon cancer, lung, esophagus, breast, liver, brain reticu-
loendothelial tissues and hemopoietic tissues cancer. The p53 pro-
tein is important for regulation of the cell cycle and serves a special
role in responding to DNA aberrations [55]. A p53-responsive gene
product, 14-3-3 isoform r, is also linked to prostate and breast
cancer. It was already known that 14-3-3 family of proteins are in-
volved in cell cycle progression, DNA damage checkpoints and
apoptosis, and it was shown recently that the 14-3-3 isoform r
functions as a regulator of mitotic translation through its direct
mitosis speciﬁc binding to a variety of translation/initiation factors.
Cells that lack 14-3-3 isoform r show impaired cytokinesis, loss of
Polo-like-kinase-1 at the midbody and accumulation of binucleate
cells [56]. Additionally, p21WAF1/CIP1 is transcriptionally regulated
by the p53 tumour suppressor. In a recent study, it was found that
inactivation of p21WAF1/CIP1 occurs in low and high grade dysplastic
nodules and together with other factors is responsible for malig-
nant transformation during hepatitis B virus associated multistep
hepatocarcinogenesis [57].
3.2.2. Mitotic checkpoint proteins
Aneuploidy in cancers is thought to be caused by chromosomal
instability. Chromosomal instability in turn has been shown to be
caused by loss of function mutations in mitotic checkpoint
proteins.
hsMAD2, the human homologue of yeast MAD2 gene is a neces-
sary component of the mitotic checkpoint, found to be low ex-
pressed in a human breast cancer cell line [58]. The mitotic
checkpoint hBUB1 is a human homologue of yeast BUB1 gene,
which controls mitotic checkpoints and chromosome segregation
in yeast. Mutations in hBUB1 were found in colorectal cancer cell
lines with chromosomal instability, suggesting that a defect in a
mitotic checkpoint is possible responsible for the formation ofaneuploidy and cancer [59]. Also, hRad9, a structural homologue
of yeast rad9, is involved in cell cycle checkpoints and apoptosis
and is a gene of 11q13 chromosomal region, which is frequently
ampliﬁed in breast cancer. hRad9 was found upregulated in breast
tumours in more than 50% of the cases and this upregulation in
some but not all tumours was due to an increase in the gene num-
ber. Overexpression correlated with a larger tumour size, suggest-
ing that the cell cycle checkpoint protein may promote breast
cancer proliferation. Correspondingly, silencing of this protein
could inhibit the proliferation of breast cancer cells in vitro. Taken
these data together, hRad9 may have a role in breast cancer pro-
gression [60].
Ataxia telangiectasia (AT) is a rare autosomal recessive disease,
characterized by cerebella ataxia, immunodeﬁciency, increased
sensitivity to ionizing radiation and predisposition to malignan-
cies, especially leukemia and lymphoid malignancies. The gene
mutated in AT is designated as ATM. The protein encoded by
ATM gene is required for cell cycle checkpoint control at the G1/
S border, S phase and G2/M checkpoints after DNA strand break-
point damage [61].
The CHK1 gene encodes for a serine/ threonine kinase involved
in the regulation of cell cycle progression and DNA damage check-
Microtubule-associated protein PRC1 
Centraspindlin complex
Chromosome passenger complex
Orbit/ASP/NuSAP 
MPP1
TBCD
ECT2
MKLP2
Polo-like kinase 1 
CEP55, Tsg101, Alix,CHMP4B 
KIF13A, FYVE-CENT,TTC19 
FIP3
CHMP1B,Spastin
septins
anillin
Fig. 2. Diagram illustrating the roles of spindle proteins that function during the various stages of cell division. DNA is indicated in blue, centrosomes in yellow and
microtubules in red.
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low in aggressive variants of human lymphoid neoplasms, where
ATM, p53 and CHK2 genes were wild type, suggesting that this pro-
tein is also important for the cell cycle regulation [62].That ﬁts
with the observation that CHK1 abrogation during mitosis causes
increased chromosome lagging and abnormal localization of Aur-
ora B. Cells lacking CHK1 present cytokinesis failure and multinu-
cleation [39]. The hCHK2 gene encodes the human homolog of
the yeast Cds1 and Rad53G2 checkpoint kinases, which are acti-
vated in response to DNA damage thereby preventing cellular en-
try into mitosis, and they also regulate DNA repair and apoptosis.
After DNA damage, hCHK2 is phosphorylated and activated by
ATM dependent and independent mechanisms and phosphorylates
downstream effector molecules, including p53, CDC25, BRCA1,
PML and E2F-1. Mutations in hCHK2 occur in Li-Fraumeni syn-
drome, a rare familial multicancer syndrome characterized by the
occurrence of sarcomas, breast cancer, brain tumours, leukemia
and adrenal cortical tumours and its expression is downregulated
in Hodgkin’s lymphoma cell lines as well as in urinary bladder can-
cer[63–65]. The chfr gene is also a checkpoint gene for mitosis that
also functions in a very early stage before chromosome condensa-tion. This checkpoint is found mutated in human lung cancer, sup-
porting the above data [66].
Another protein implicated in cell cycle checkpoints and cancer
is BRCT-repeat inhibitor of hTERT expression, BRIT1, which func-
tions as a factor in the DNA damage checkpoints that control multi-
ple damage sensors and early mediators and regulates important
molecules in the cell cycle checkpoint, thus affecting the timing
of mitosis. BRIT1 is found in very low expression in breast cancer
cell lines and in human epithelial tumours of the ovary and pros-
tate compared to normal tissues. In addition, the loss of gene copy
number of BRIT1 correlated with genomic instability and in loss of
function defect in response to DNA damage. Also, BRIT1 has been
shown to correlate with the occurrence of metastasis, suggesting
that it might contribute to tumour aggressiveness. All these data
indicate the importance of BRIT1 defects in cancer progression
[67].
Finally, septins are important in regulating the cell cycle check-
point and it was recently found that SEPT2, SEPT8, SEPT9 and
SEPT11 were upregulated in various tumours, whereas SEPT4 and
SEPT10 were down regulated in most cancer types. The abnormal
expressions were in accordance with the tumour malignances or
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tins may play an important role in carcinogenesis. It is also known
that SEPT5, SEPT6, SEPT9 and SEPT11 were found mutated in infant
acute leukemia patients [68]. Anillin, which interacts with septins,
is also implicated in carcinogenesis. Expression levels of anillin
correlate with metastatic potential of human tumours of various
kinds and inhibition of anillin expression is shown to suppress
the growth of lung cancer cells in culture [69].
3.2.3. Mitotic regulators
BRCA1 has been implicated as an important factor involved in
DNA repair and in regulation of cell cycle checkpoints in case of
DNA damage. BRCA1 is well known that is found mutated in 50%
of inherited breast cancer cases and the acquisition of a single
defective allele leads to elevated predisposition to both breast
and ovarian cancer. Cells with BRCA1 mutations present increased
genomic instability and elevated levels of chromosome aberrations;
therefore it is obvious that BRCA1 has a very important function
in DNA damage response [70]. Inositide-speciﬁc phospholipase c
b1 is another regulator of cell cycle. This enzyme is involved in
the progression of myelodysplastic syndrome, a hematological
disease that evolves into acute myeloid leukemia in about 30% of
the cases [71].
FEZ1/LZTS1 is a recently identiﬁed mitotic regulator implicated
in cancer development. It has been found that LZTS1 absence de-
creases CDK1 activity by affecting CDC25. CDC25 is a key activator
of the CDKs. It has been proposed that in G2/M arrested cells,
CDC25 may be efﬁciently ubiquitinated. LZTS1 was found to be in-
volved in CDC25 ubiquitination by protecting it from proteasome
degradation during M phase, thereby regulating CDK1 activity.
The expression of LZTS1 has been found reduced in various types
of cancers: primary gastric cancer, primary transitional cell carci-
noma of bladder, Bellini duct carcinoma, lung cancer, in primary
esophageal cancer, prostate cancer and other types of cancer. All
these data indicate that indeed LZTS1 can be regarded as a cell cycle
regulator and is involved in carcinogenesis [72].
Depletion of a novel centrosomal protein, centrobin, inhibits
centriole duplication and leads to impaired cytokinesis. It is also
found to inhibit the proliferation of a lung cancer cell line and pre-
vented the G1 to S transition of the cells, via the upregulation of
p53, which is associated with the activation of cellular stress in-
duced by the p38 pathway. Interestingly, inhibition of p38 activity
could overcome the cell cycle arrest caused by centrobin depletion.
These data indicate the importance of centrobin for cell cycle reg-
ulation [73].
3.2.4. Kinases
Protein kinases play a very central role in cell cycle regulation
and also orchestrate molecular events in cytokinesis. Aurora A, a
serine-threonine kinase has a variety of functions, including cen-
trosome maturation and separation, bipolar spindle assembly,
chromosome alignment and the transition from prophase to
metaphase as well as cytokinesis. Aurora A is frequently overex-
pressed in human cancers, including hepatocellular carcinoma.
Recent studies in transgenic mice overexpressing human Aurora
A in the liver revealed a p53 dependent premitotic arrest during
liver regeneration, clarifying the role of Aurora A in tumourigen-
esis [74]. The related kinase Aurora B is also very important for
cell cycle and cancer progression [5]. Recent data show that the
bromodomain protein Brd4 controls the transcription of Aurora
B. Depletion of Brd4 results in cytokinesis failure in cancer cells,
which is also observed after Aurora B depletion [75]. Also, Aur-
ora 2 kinase (STK15) is found overexpressed in various types of
cancer lines, such as breast, ovarian, colon, prostate, neuroblas-
toma and cervical cancers. Its overexpression leads to centro-
some ampliﬁcation, chromosomal instability and transformation[76]. Polo-like kinase 1 (PLK1) also belongs to the family of ser-
ine/threonine kinases and plays an important role in centrome
maturation, bipolar spindle formation and cytokinesis during
mitosis. PLK1 was found to be overexpressed in human leukemia
cell lines as well as in cell samples from individuals with acute
myelogenous leukemia and acute lymphoblastic leukemia, again
suggesting its role in cancer progression [77]. Another serine/
threonine protein kinase, citron, is also important for cytokinesis.
Its localization to the central spindle depends on the kinesin-3
motor KIF14, and vice versa [23]. The overexpression of KIF14
in retinoblastoma suggests a possible involvement of the cit-
ron-KIF14 axis in carcinogenesis [78].3.2.5. Other cytokinesis regulator proteins in cancer
Apart from proteins involved in mitosis checkpoints and in the
cell cycle regulation, there are also additional proteins involved in
cytokinesis that are found mutated in various cancers. Rab21 is a
small GTPase that associates with several integrin a subunits. Re-
cent data indicate that Rab21 activity, integrin-Rab21 association
and integrin endocytosis are necessary for normal cytokinesis.
Importantly, the RAB21 gene was found mutated in ovarian carci-
noma cell lines and in a prostate cancer tumour sample. Cells con-
taining these mutations accumulate multinucleated proﬁles, in line
with the notion that Rab21 controls cytokinesis [79]. KLHDC8B
gene was recently characterized and it was found to be disrupted
by translocations found in a family in which multiple individuals
developed Classical Hodgkin lymphoma. This gene encodes a pro-
tein that contains seven kelch repeat domains and localizes to
the midbody. Depletion of the protein results in binucleated cells
indicating that it is necessary for cytokinesis [80]. GATA6 is a tran-
scription factor that functions in early embryonic stem cell differ-
entiation. This factor is usually lost in ovarian cancer. Depletion of
GATA6 leads in cytokinesis failure, deformation of nuclear enve-
lope and formation of polyploid and aneuploid cells. Thus GATA6
is also linked to tumourigenesis [81]. Finally, the cytokinesis regu-
lator FYVE-CENT is found mutated in breast cancer samples [82].
Depletion of this protein results in an increased number of binu-
clear and multinuclear proﬁles, as well as cells arrested in cytoki-
nesis, indicating its important role in cytokinesis [34].4. Conclusions and perspectives
There is now a substantial body of evidence suggesting that
aberrant cytokinesis may lead to aneuploidy, which may in turn
develop into cancer. Multiple components of the machineries that
mediate and regulate cytokinesis have been identiﬁed and func-
tionally characterized, and some of these have clear associations
to cancer. Nevertheless, there is still no conclusive evidence that
cytokinesis failure may cause carcinogenesis and further research
is warranted in order to prove or disprove this hypothesis. If the
hypothesis is indeed correct, a question that arises is whether cyto-
kinesis and its components can be targeted for the prevention or
treatment of cancer. One central idea is the abrogation of G2 as
anticancer strategy. For this purpose, possible targets could be
the ATM, WEE1, and CHK1. ATM and WEE1 inhibitors are currently
in development and CHK1 inhibitors are now in phase I/II of clini-
cal trials [83]. PLK1 and Aurora kinases are also attractive drug tar-
gets, which are already in clinical trials [1,77]. Because cytokinesis
failure is thought to be a relatively early event in carcinogenesis, it
is also possible that detection of such aberrations might be
exploited for early detection of cancers, which in turn would im-
prove the therapeutic endpoints. In conclusion, future research
on cytokinesis has the potential to yield novel insight that could
satisfy the curiosity of cell biologists, and at the same time be ben-
eﬁcial to cancer patients.
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